| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Questioning the 18F-FDG lump constant: Krohn and colleagues examine the relevance of the 18F-FDG lump constant in quantitative small animal models of regional brain imaging and pose key questions about a related article in this month's JNM.
Page 5
Nasopharyngeal PET/CT uptake patterns: Chen and colleagues evaluate 18F-FDG uptake on PET/CT to determine whether characteristic patterns and intensities in areas of Waldeyer's ring can improve the ability to differentiate benign from malignant lesions.
Page 8
|
Interpreting 18F-FDG–negative lung nodules: O and colleagues explore the diagnostic challenge of interpreting small pulmonary nodules with little or no perceptible 18F-FDG uptake and provide insight on strategies for follow-up.
Page 15
Deep breath-hold PET/CT: Nehmeh and colleagues describe their experience with inspiration breath-hold techniques in PET/CT imaging of the thorax and outline the technical aspects required for routine clinical use in reduction of motion artifacts.
Page 22
Assessing presynaptic dopaminergic deficit: Koch and colleagues report on studies in humans demonstrating the use of 99mTc-NC100697, a new formulation of 99mTc-TRODAT-1, for estimating presynaptic striatal dopamine transporter binding and discuss potential applications in parkinsonian syndromes.
Page 27
|
PET and PET/CT in FUO: Meller and colleagues provide an overview of 18F-FDG PET and PET/CT in the diagnosis of fever of unknown origin, focusing on the ability of PET to diagnose a wider spectrum of disease at earlier stages than conventional approaches.
Page 35
|
Differential prostate diagnosis: Oka and colleagues explore the feasibility of anti–18F-FACBC for diagnosing prostate cancer through in vitro and in vivo rat models and assess the potential of this tracer for distinguishing cancer from inflammation and benign prostatic hyperplasia.
Page 46
|
Anti–18F-FACBC and prostate cancer: Schuster and colleagues examine the uptake of this synthetic L-leucine analog on PET/CT in patients with newly diagnosed and recurrent prostate carcinoma.
Page 56
Imaging with 64Cu-MSH peptide: Wei and colleagues report on the synthesis and initial biologic evaluation of a novel 64Cu-labeled candidate for PET imaging of malignant melanoma.
Page 64
|
Primary and metastatic melanoma imaging: Miao and colleagues assess the potential utility of 99mTc- and 111In-labeled 
-melanocyte–stimulating hormone peptides as SPECT/CT imaging probes, using mouse models of primary and metastatic melanoma.
Page 73
P-glycoprotein and PET radioligands: Ishiwata and colleagues investigate the extent to which P-glycoprotein affects 8 radioligands used clinically for PET studies of brain function.
Page 81
Androgen regulation of GRP receptors: de Visser and colleagues evaluate gastrin-releasing peptide receptor expression in 12 established human prostate xenograft models representing progressive disease stages and assess the effect of antiandrogen treatment on each.
Page 88
Lumped constant for small-animal 18F-FDG PET: Tokugawa and colleagues determine an operational value for the lumped constant to be used in measurements of the local rate of cerebral glucose use in 18F-FDG PET imaging of normal adult male rats.
Page 94
Dosimetry of 18F-SPA-RQ: Sprague and colleagues apply 3 methods of image analysis to estimate the radiation safety profile and relative risks of a novel selective radioligand for in vivo PET quantification of tachykinin NK1 receptors.
Page 100
Iterative segmentation of PET volumes: Jentzen and colleagues report on an iterative thresholding method to estimate PET volumes without a priori anatomic knowledge and describe its application to clinical images.
Page 108
Submillimeter LSO array for PET: Stickel and colleagues provide a description of a small-animal PET configuration designed to meet the increasing demands for high-spatial-resolution imaging in mouse models of disease.
Page 115
|
Metastatic bone pain palliation: Ogawa and colleagues evaluate the palliative effects of a 186Re-complex–conjugated bisphosphonate in an animal model of metastatic bone pain.
Page 122
Radiation dosimetry of 11C-PIB: Scheinin and colleagues investigate the biodistribution and radiation dosimetry of the PET amyloid imaging agent 11C-PIB in humans.
Page 128
Kidney dose distribution for PRRT: Konijnenberg and colleagues report on the biodistribution of octreotides used in peptide receptor radionuclide therapy and discuss potential challenges in accurate modeling of renal tissue damage.
Page 134
|
Normal organ dosimetry with quantitative PET: Kolbert and colleagues describe a method for determining normal organ 131I dosimetry in patients undergoing radioiodide therapy for thyroid cancer by use of serial scanning with 124I PET.
Page 143
131I vs. 90Y lung dosimetry in NHL: Song and colleagues use Monte Carlo–based dosimetry to compare the potential of 90Y and 131I in targeted therapy of lung metastases of various nodule sizes and tumor burdens in non-Hodgkin's lymphoma.
Page 150
Supervised clustering for PET: Turkheimer and colleagues combine reference region modeling with supervised reference tissue extraction to produce a robust and reproducible quantitative assessment technique for 11C-(R)-PK11195 PET studies in the human brain.
Page 158
|
| ON THE COVER
Conventional imaging techniques have serious limitations in the detection, staging, and restaging of prostate carcinoma. PET/CT using anti–1-amino-3-18F-fluorocyclobutane-1- carboxylic acid (anti–18F-FACBC), a synthetic L-leucine analog, has demonstrated uptake in prostate carcinoma even when no uptake was found on 111In-capromab pendetide imaging. It is feasible that the use of anti–18F-FACBC might improve the diagnostic imaging of both initial and recurrent prostate carcinoma.
SEE PAGE 61
|
Related articles in JNM:
-MSH Peptide Analog Using a Cross-Bridged Cyclam Chelator
-Melanocyte-Stimulating Hormone Peptides as Imaging Probes for Primary and Pulmonary Metastatic Melanoma Detection
| ||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
